New Insights About Doxorubicin-Induced Toxicity to Cardiomyoblast-Derived H9C2 Cells and Dexrazoxane Cytoprotective Effect: Contribution of In Vitro (1)H-NMR Metabonomics

Doxorubicin (DOX) is an anticancer drug widely used in oncology. The main limitation to DOX treatments though is due to the cumulative dose that may lead to cardiotoxicity. Clinically, DOX-induced cardiomyopathy develops as a progressive heart failure consecutive to a progressive loss in cardiomyocy...

Descripción completa

Detalles Bibliográficos
Autores principales: Dallons, Matthieu, Schepkens, Corentin, Dupuis, Aurélie, Tagliatti, Vanessa, Colet, Jean-Marie
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2020
Materias:
Pharmacology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7044126/
https://www.ncbi.nlm.nih.gov/pubmed/32153402
http://dx.doi.org/10.3389/fphar.2020.00079

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7044126/
https://www.ncbi.nlm.nih.gov/pubmed/32153402
http://dx.doi.org/10.3389/fphar.2020.00079

Ejemplares similares